Tristel disinfectant product wins key US approval
A potentially lucrative product drive in the United States for Tristel plc in Newmarket has been underpinned by receipt of a key approval from the United States Environmental Protection Agency (EPA). It originally granted Tristel approval for Jet – its foam-based disinfectant for surfaces – in April 2018.
Tristel successfully enhanced the performance claims of the product with a second approval in January 2019 and then registered the product in three States before curtailing the nationwide registration programme until a third submission could be made to bolster further the competitive positioning of the product.
This submission was made in October 2020 and Tristel has now received the third approval for Jet. This expands the product’s efficacy claims to include mycobacteria and all efficacy claims are within a contact time of two minutes.
Tristel expects to complete State-by-State registration by the end of June 2022, including California where its existing registration will require amendment, which can be a lengthy process.
The company has appointed Parker Laboratories in New Jersey as its United States manufacturing partner for Jet and will sell the product through Parker’s nationwide network of distributors on a non-exclusive basis, starting in FY23. Other distribution channels will be put in place ahead of the US launch.
Jet is a powerful sporicidal disinfectant and can be used on medical device surfaces located near to the patient. It is also a powerful cleaner destroying RNA and DNA in seconds.
In other successes for its broad-based portfolio, Tristel Duo OPH has been approved by Health Canada as a class 2 medical device and is included in Health Canada’s Medical Device License Listing.
Duo OPH is a high-level disinfectant intended for use on ophthalmic instruments including ultrasound devices and re-usable tonometers and lenses that contact the cornea.
Tristel sells Duo OPH in over 15 countries and worldwide sales in FY21 will be approximately £650,000. Duo OPH is said to be the only specialist high-level disinfection product for ophthalmic devices in the world.
Awareness of the need for high-level disinfection in diagnostic eye care is growing, although COVID-19 caused ophthalmologists and optometrists in all countries to curtail their activities in 2020.
Parker Laboratories will manufacture the product and Tristel is in discussions with potential distribution partners in Canada.
Tristel is also gathering momentum in Asia. The South Korea Ministry of Food and Drug Safety granted approval for the Tristel Sporicidal Wipe from the Korean Ministry of Food and Drug Safety in March 2019.
The application had taken four years as Tristel’s chlorine dioxide chemistry had to achieve approval as a new drug. Tristel Duo ULT has now been approved as a high-level disinfectant for ultrasound devices, and with Trio will be sold throughout South Korea by HP&C – Tristel’s distributor since 2013.
Duo is a hand-held dispenser which applies the company’s powerful chlorine dioxide chemistry as a foam to the surface of medical devices.
Tristel Duo is widely used throughout Europe, the Middle East and the Asia-Pacific region and the company is seeking approval for Duo ULT from the United States Food and Drug Administration (FDA).
Worldwide sales of all Duo branded products for medical device disinfection, including Duo ULT and Duo OPH, will exceed £4.3m in FY21.
Paul Swinney, CEO of Tristel said: “Every regulatory approval we achieve represents an important milestone in our progress, and these three approvals are very significant.
“The enhanced claim set that we have achieved for Jet now justifies taking the product through state-wide registration in the US and gearing up our manufacturing and distribution partnership with Parker Laboratories.
“The approval of Duo OPH by Health Canada represents our first successful registration of a medical device high-level disinfectant in North America. We are actively pursuing a submission to the USA FDA for Duo ULT and we are buoyed by this successful application in Canada.
“The approval in South Korea increases the visibility of our chlorine dioxide technology in the country and extends our distributor’s involvement into more clinical areas within a hospital.”